Description: Immunotech Laboratories, Inc. develops and commercializes proprietary proteins for use in treating human immunodeficiency virus (HIV), acquired immune deficiency syndrome (AIDS), hepatitis, and other immuno-related disorders. Its flagship compound is ITV-1 (immune therapeutic vaccine), a suspension of irreversible pepsin fraction that is used in the treatment of HIV/AIDS and Hepatitis C, as well as to modulate the immune system. The company is headquartered in Monrovia, California. As of June 14, 2017, Immunotech Laboratories, Inc. operates as a subsidiary of Eco-Petroleum Solutions, Inc.
Home Page: www.immunotechlab.com
120 West Pomona Avenue
Monrovia,
CA
91016
United States
Phone:
626-538-4779
Officers
| Name | Title |
|---|---|
| Mr. Harry H. Zhabilov Jr. | Founder, Vice Chairman, Pres, Chief Science Officer & Sec. |
| Billy Ray | CFO, Exec. of Bus. and Devel. & Member of Advisory Board |
| Mr. Adam S. Tracy Esq., J.D., MBA | Legal Counsel |
| Dr. Edward Azizian | Sr. VP of Grants Research |
Exchange: OTCCE
Country: US
Currency: US Dollar ($)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 4 |